XM does not provide services to residents of the United States of America.

Trillionaire club throws an indulgent theme party



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>BREAKINGVIEWS-Trillionaire club throws an indulgent theme party</title></head><body>

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. Refiles to fix spacing in paragraph three.

By Robert Cyran

NEW YORK, June 20 (Reuters Breakingviews) -The trillionaire club is growing quickly. Six years ago, Apple AAPL.O became the charter member, not long before oil titan Saudi Aramco 2223.SE publicly debuted with a 13-digit market capitalization. Few would have predicted five more inductees so soon, and investors are nudging even more companies to join. Chipmaker Broadcom AVGO.O is riding an artificial intelligence wave just like Nvidia NVDA.O, Microsoft MSFT.O, Amazon.com AMZN.O, Alphabet GOOGL.O and Meta Platforms META.O. Eli Lilly LLY.N is on its way thanks to the anti-obesity craze. Hyped megatrends sparking giddy valuations, however, will inevitably lead to disappointment.

Broadcom, under boss Hock Tan, has been expanding by acquisition. It bought several rivals before paying almost $70 billion last year for cloud-computing software developer VMware. The deals have enabled it to slash costs and raise prices. The $839 billion company’s total return for shareholders, including reinvested dividends, has been an eye-popping 3,200% over the past decade. Its AI-linked chips also have started to draw comparisons to Nvidia, which just overtook Microsoft as the world’s most valuable company and whose $3.3 trillion market cap exceeds the entire Russell 2000 Index .RUT.

Lilly, at $847 billion, is cashing in on the surging desire for weight-loss medications. Its Zepbound molecule, also used to treat diabetes, generated $5.3 billion of revenue last year. The only limitation now is production, as the market it shares with Novo Nordisk NOVOb.CO rumbles toward $100 billion annually by 2030, according to Goldman Sachs analysts.

The doubling of Broadcom’s and Lilly’s market values in a year makes thematic investing seem easy and the somewhat arbitrary expectations fun. Even Warren Buffett’s Berkshire Hathaway BRKa.N conglomerate is on track to be part of the group, boosted by its large holding of Apple stock. It’s easy to forget that fiberoptics and Dow 10,000 hats were all the rage in 1999, and darkly ironic a decade later.

Both the chipmaker and the drugmaker also face valid questions about whether their valuations reflect overly excessive growth projections. Lilly trades at 18 times anticipated revenue for the next 12 months, or more than 3 times peer Merck’s MRK.N multiple, based on LSEG data. Its patent protection will eventually lapse, however, and rivals could roll out better therapies even sooner.

Broadcom’s stock trades at 32 times estimated earnings, or twice its 10-year average. Its most recent quarterly revenue increased just 12% from a year earlier after excluding VMware’s contributions; semiconductor sales grew 6%. Other companies built around buying and cutting, such as cheese-and-ketchup purveyor Kraft Heinz KHC.O, have struggled to sustain the business model. It all makes the four-comma theme party look indulgent.

Follow @rob_cyran on X



CONTEXT NEWS

As of June 14, Apple, Microsoft, Nvidia, Alphabet, Amazon.com and Meta Platforms all had market capitalizations of more than $1 trillion. Saudi Arabian oil producer Saudi Aramco’s valuation also exceeded the threshold.


Graphic: Lilly and Broadcom make outperformance look easy Lilly and Broadcom make outperformance look easy https://reut.rs/3VHtMN3


Editing by Jeffrey Goldfarb and Sharon Lam

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.